Dermatology Update 2016
SESSIONS & ABSTRACTS
Montréal, Le Centre Sheraton - NOVEMBER 3-6, 2016
An Update on the Treatment Landscape for Onychomycosis
Onychomycosis is a common nail infection. Traditionally, treatment for onychomycosis has consisted of oral antifungal agents. Recent research and publications in onychomycosis provide new insights on disease etiology and management.
Recent data show that onychomycosis caused by mixed dermatophyte/nondermatophyte molds may be more prevalent than previously thought. This may have implications for treatment of onychomycosis. Although oral and topical agents for onychomycosis are approved for dermatophytes, many antifungals show a broad spectrum for multiple organisms. Efinaconazole 10% solution has a broad spectrum of activity, with demonstrated in vitro activity against dermatophytes, nondermatophyte molds, and yeasts.
Certain onychomycosis patient populations have limited treatment options. These populations include patients with mixed infections, children, elderly, and certain subsets of individuals who are immunocompromised. Efinaconazole may provide a treatment option, albeit off-label, for these patients. Additionally, certain subsets of traditionally enrolled trial participants may respond more quickly to topical treatment with efinaconazole, for example, younger subjects, females, and individuals without, or with effectively treated, tinea pedis.
Recurrence and reinfection has also become a relevant issue, with various prevention strategies available. The use of prophylactic antifungals in preventing recurrence requires study. Using efinaconazole as a prophylactic measure may have value in the long-term management of onychomycosis.